Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors
November 15, 2022 16:00 ET
|
Virogin Biotech
VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study...
Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers
September 08, 2022 15:01 ET
|
Virogin Biotech Canada
VANCOUVER, British Columbia & HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, and The University of Texas MD Anderson Cancer Center today announced...
Global Oncolytic Virus Therapy Market 2026 Companies Clinical Trials Insight
November 02, 2020 03:37 ET
|
KuicK Research
DELHI, India, Nov. 02, 2020 (GLOBE NEWSWIRE) -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights: Global Oncolytic Virus...
Global Oncolytic Virus Immunotherapy Market A US$ 700 Million Opportunity By 2026
October 08, 2020 13:19 ET
|
KuicK Research
DELHI, India, Oct. 08, 2020 (GLOBE NEWSWIRE) -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights: Global Oncolytic Virus...
Imvaq Therapeutics Raises $15 Million in Series B Financing to Fund IND and Phase 1 Trials
September 28, 2020 09:00 ET
|
Imvaq Therapeutics
NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Imvaq Therapeutics Corp., an innovative cancer immunotherapy company founded by world-leading researchers at Memorial Sloan Kettering Cancer Center...